KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Idexx Laboratories (IDXX) over the last 17 years, with Q3 2025 value amounting to $35.7 million.

  • Idexx Laboratories' Current Deferred Revenue fell 713.17% to $35.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.7 million, marking a year-over-year decrease of 713.17%. This contributed to the annual value of $33.8 million for FY2024, which is 913.03% down from last year.
  • Per Idexx Laboratories' latest filing, its Current Deferred Revenue stood at $35.7 million for Q3 2025, which was down 713.17% from $36.3 million recorded in Q2 2025.
  • Idexx Laboratories' Current Deferred Revenue's 5-year high stood at $41.6 million during Q1 2021, with a 5-year trough of $33.8 million in Q4 2024.
  • Moreover, its 5-year median value for Current Deferred Revenue was $38.0 million (2024), whereas its average is $38.4 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first skyrocketed by 1325.27% in 2021, then crashed by 913.03% in 2024.
  • Over the past 5 years, Idexx Laboratories' Current Deferred Revenue (Quarter) stood at $40.0 million in 2021, then decreased by 5.24% to $37.9 million in 2022, then fell by 1.96% to $37.2 million in 2023, then fell by 9.13% to $33.8 million in 2024, then rose by 5.6% to $35.7 million in 2025.
  • Its Current Deferred Revenue stands at $35.7 million for Q3 2025, versus $36.3 million for Q2 2025 and $35.0 million for Q1 2025.